BIOJAMP ™: A Range of Biosimilars for a Seamless Approach

• BIOJAMP^TM, a division within the JAMP Pharma Group, is dedicated to improving and simplifying the complex world of biosimilars for patients and healthcare professionals.

• BIOJAMP^TM and its JAMP Care^TM patient support program offer a seamless experience for patients and healthcare professionals.

• BIOJAMP^TM also aims to promote a range of products that will offer significant savings to provinces and insurers.

• BIOJAMP^TM has acquired the commercial rights to a portfolio of biosimilar products which, in combination with the Group’s other launches, will position it at the forefront of Canada’s pharmaceutical industry.

BOUCHERVILLE, QC, Feb. 1, 2022 /CNW/ – The JAMP Pharma Group, a Montreal-based Canadian pharmaceutical company founded over 30 years ago, announced today the creation of its all-new division, BIOJAMP^TM. Its mission is to offer biosimilar products aimed at improving the experience of patients and healthcare professionals, at a considerably lower cost than the reference product. By creating this division, the JAMP Pharma Group is displaying its desire and potential to establish itself as a Canadian leader in the biosimilars market.

To achieve this ambitious objective in the biologics market, already a multi-billion-dollar industry in Canada, BIOJAMP^TM intends to set itself apart from the competition by simplifying the complex process of transitioning to biosimilars. BIOJAMP^TM and its JAMP Care^TM support program will also make access to treatment more affordable, while providing a range of additional services without compromising the program’s simplicity.

This new division within the JAMP Pharma Group will play an important role in the objectives of provinces and insurers looking to increase recurring annual savings through the use of biosimilars. The JAMP Pharma Group is focusing all its efforts on becoming a key actor and consolidating its mission: help build a future where everyone can live full and healthy lives.

Story continues

A Vital Partnership

It is worth noting that the creation of BIOJAMP^TM is primarily made possible through an exclusive agreement with Alvotech, a world-class biopharmaceutical company entirely specialized in developing and manufacturing high-quality biosimilar medicines. Aligning Alvotech’s fully integrated model with BIOJAMP^TM‘s commercial infrastructure and expertise will give Canadian patients access to a wide range of biosimilar products while significantly reducing healthcare system costs. This agreement and JAMP Pharma Group’s consistent rapidly paced launches are strategic imperatives that support the Group’s ambitions to become Canada’s largest pharmaceutical company.

Quotes

“At JAMP Pharma Group, we’re always listening to the needs of Canadians and healthcare professionals, as Canadians ourselves. The launch of Simlandi^TM, the first product to be commercialized by BIOJAMP^TM, is a novel formulation of adalimumab, never launched by a Canadian company despite the fact that this formulation is established as a standard of care in the United States and Europe. We’d be hard pressed to find a better example to clearly illustrate our commitment to meeting the specific needs of patients and healthcare professionals.”

“BIOJAMP^TM aims to simplify the experience of patients by reducing barriers and facilitating the transition process. As an example, we are proud to have developed an auto-injector designed for patients with dexterity challenges, who will now be able to operate the Simlandi^TM auto-injector more confidently. We will also commercialize a new and unique-to-Canada 80 mg/0.8 mL, format which will reduce the number of injections for certain types of patients.”

About JAMP Pharma Group

The Jamp Pharma Group is a Canadian-owned company headquartered in the Montreal area. Having experienced remarkable growth over the past 10 years, the JAMP Pharma Group is active in all segments of the pharmaceutical market thanks to a portfolio of close to 300 molecules. The Group is among the industry leaders in terms of annual prescription volume[1]. With nearly 40 new products approved by Health Canada in the past year, the JAMP Pharma Group is the Canadian leader in product launches[2], broadening the new treatment options available in Canada, including many specialty drugs. The Group also has a Wampole—Laboratoire Suisse Division with more than 180 over-the-counter products including a wide range of vitamins, supplements, and natural products, as well as prescription and branded products from its subsidiary Orimed Pharma.

JAMP Pharma Group

SOURCE JAMP Pharma

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2022/01/c9859.html

Source